369 related articles for article (PubMed ID: 28693519)
21. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E;
Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329
[TBL] [Abstract][Full Text] [Related]
22. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
[TBL] [Abstract][Full Text] [Related]
23. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
[TBL] [Abstract][Full Text] [Related]
24. Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes.
Chew JK; Zhu M; Broadhead GK; Luo K; Hong T; Chang AA
Ophthalmologica; 2017; 238(1-2):23-30. PubMed ID: 28395293
[TBL] [Abstract][Full Text] [Related]
25. Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration: A Discrete Choice Experiment.
Mueller S; Agostini H; Ehlken C; Bauer-Steinhusen U; Hasanbasic Z; Wilke T
Ophthalmology; 2016 Apr; 123(4):876-83. PubMed ID: 26778346
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for conversion to neovascular age-related macular degeneration based on longitudinal morphologic and visual acuity data.
Friberg TR; Bilonick RA; Brennen PM
Ophthalmology; 2012 Jul; 119(7):1432-7. PubMed ID: 22551740
[TBL] [Abstract][Full Text] [Related]
27. Treatment satisfaction of patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents.
Marakis TP; Koutsandrea C; Chatzistefanou KI; Tountas Y
Int Ophthalmol; 2018 Apr; 38(2):565-576. PubMed ID: 28285389
[TBL] [Abstract][Full Text] [Related]
28. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
Fletcher EC; Lade RJ; Adewoyin T; Chong NV
Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
[TBL] [Abstract][Full Text] [Related]
29. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee H; Ji B; Chung H; Kim HC
Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
31. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
Bressler NM; Chang TS; Varma R; Suñer I; Lee P; Dolan CM; Ward J; Ianchulev T; Fine J
Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS
Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807
[TBL] [Abstract][Full Text] [Related]
33. Vision-related quality of life in patients with bilateral severe age-related macular degeneration.
Cahill MT; Banks AD; Stinnett SS; Toth CA
Ophthalmology; 2005 Jan; 112(1):152-8. PubMed ID: 15629836
[TBL] [Abstract][Full Text] [Related]
34. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY REVEALS BLOOD FLOW IN CHOROIDAL NEOVASCULAR MEMBRANE IN REMISSION PHASE OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Ichiyama Y; Sawada T; Ito Y; Kakinoki M; Ohji M
Retina; 2017 Apr; 37(4):724-730. PubMed ID: 28248824
[TBL] [Abstract][Full Text] [Related]
35. Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine.
Finger RP; Hoffmann AE; Fenwick EK; Wolf A; Kampik A; Kernt M; Neubauer AS; Hirneiss C
Br J Ophthalmol; 2012 Jul; 96(7):997-1002. PubMed ID: 22535331
[TBL] [Abstract][Full Text] [Related]
36. Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration--a report of 1 year results.
Lüke M; Ziemssen F; Bartz-Schmidt KU; Gelisken F
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1831-6. PubMed ID: 17347809
[TBL] [Abstract][Full Text] [Related]
37. The role of social deprivation in severe neovascular age-related macular degeneration.
Sharma HE; Mathewson PA; Lane M; Shah P; Glover N; Palmer H; Haque MS; Denniston AK; Tsaloumas MD
Br J Ophthalmol; 2014 Dec; 98(12):1625-8. PubMed ID: 24997180
[TBL] [Abstract][Full Text] [Related]
38. [Natural course and prognosis of visual acuity in patients of age-related macular degeneration with occult choroidal neovascularization].
Zhang CF; Li ZQ; Du H; Han BL
Zhonghua Yan Ke Za Zhi; 2003 Jul; 39(7):415-8. PubMed ID: 12921672
[TBL] [Abstract][Full Text] [Related]
39. Challenges Associated with Estimating Utility in Wet Age-Related Macular Degeneration: A Novel Regression Analysis to Capture the Bilateral Nature of the Disease.
Hodgson R; Reason T; Trueman D; Wickstead R; Kusel J; Jasilek A; Claxton L; Taylor M; Pulikottil-Jacob R
Adv Ther; 2017 Oct; 34(10):2360-2370. PubMed ID: 29019023
[TBL] [Abstract][Full Text] [Related]
40. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration.
Sunness JS; Gonzalez-Baron J; Applegate CA; Bressler NM; Tian Y; Hawkins B; Barron Y; Bergman A
Ophthalmology; 1999 Sep; 106(9):1768-79. PubMed ID: 10485549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
